ライフサイエンスコーパス: cholesterol absorption

1 ced by PX20606 was independent of changes in cholesterol absorption.

2 level, bile acid composition, and intestinal cholesterol absorption.

3 olesterol absorption than in those with high cholesterol absorption.

4 lowering drug that blocks intestinal dietary cholesterol absorption.

5 lesterol gallstones by inhibiting intestinal cholesterol absorption.

6 contributes to the regulation of intestinal cholesterol absorption.

7 mann-Pick C1-like 1 (NPC1L1) is required for cholesterol absorption.

8 es plasma cholesterol by blocking intestinal cholesterol absorption.

9 dly emerged as a key regulator of intestinal cholesterol absorption.

10 1L1), a gene that is required for intestinal cholesterol absorption.

11 rophilic bile salt pool decreased intestinal cholesterol absorption.

12 mibe, suggesting a possible role for CAV1 in cholesterol absorption.

13 enterocytes that is critical for intestinal cholesterol absorption.

14 sensitive pathway responsible for intestinal cholesterol absorption.

15 olesterol that act in the intestine to lower cholesterol absorption.

16 h studies is a possible role for the gene in cholesterol absorption.

17 glyceride is necessary for efficient dietary cholesterol absorption.

18 lipoprotein synthesis, and (iii) intestinal cholesterol absorption.

19 ted with substantial decreases in intestinal cholesterol absorption.

20 -cell formation, and for ACAT2 in intestinal cholesterol absorption.

21 nally thought to be its mediation of dietary cholesterol absorption.

22 to participate in the regulation of dietary cholesterol absorption.

23 novel pharmacological approaches to inhibit cholesterol absorption.

24 es correlated with the percentage of dietary cholesterol absorption.

25 o the bile and suppressed percentage dietary cholesterol absorption.

26 ers but does not play a primary role in free cholesterol absorption.

27 c enzymes, tissue BA levels and triglyceride/cholesterol absorption.

28 r knockdown of NPC1L1 attenuated CCK-induced cholesterol absorption.

29 ed CCK-induced NPC1L1-Rab11a interaction and cholesterol absorption.

30 CK2R with antagonists attenuated CCK-induced cholesterol absorption.

31 pressed CCK-induced NPC1L1 translocation and cholesterol absorption.

32 D19H of ABCG8 are associated with diminished cholesterol absorption.

33 rol levels that equally represent markers of cholesterol absorption.

34 s accelerated RCT by compromising intestinal cholesterol absorption.

35 Both ezetimibe and phytosterols inhibit cholesterol absorption.

36 erol secretion without increasing intestinal cholesterol absorption.

37 olesterol secretion, but inhibits intestinal cholesterol absorption.

38 cholesterol transport and reduces intestinal cholesterol absorption.

39 erstanding EZE inhibition of NPC1L1-mediated cholesterol absorption.

40 pectively) and reduced percentage intestinal cholesterol absorption (-10 +/- 1% and -25 +/- 3%, respe

41 eight), a more efficient level of intestinal cholesterol absorption (41.1% vs. 25.3%), and a lower ra

42 t resulted in significantly lower intestinal cholesterol absorption (598 mg/d; 95% confidence interva

43 reatment significantly increased (P = 0.013) cholesterol absorption (72.6% +/- 2.9%) compared with di

44 as identified to be essential for intestinal cholesterol absorption, a process that is sensitive to a

45 synthesis in liver, and inhibits intestinal cholesterol absorption, actions that would collectively

46 stinal lumen is a prerequisite for efficient cholesterol absorption, additional enzyme(s) can compens

47 ariations identified in individuals with low cholesterol absorption affect protein function, we perfo

48 ciency results in a significant reduction in cholesterol absorption, although other enzymes in the di

49 menal bile with CA results in an increase in cholesterol absorption, an effect potentially mediated b

50 C1-Like 1 (NPC1L1) as a critical mediator of cholesterol absorption and an essential component of the

51 rotein E (apoE) in the regulation of dietary cholesterol absorption and biliary cholesterol excretion

52 allstones by effectively reducing intestinal cholesterol absorption and biliary cholesterol secretion

53 Thereafter, cholesterol absorption and cholesterol fractional synthe

54 ntial for jejunal function including fat and cholesterol absorption and confirm that GATA4 plays a pi

55 s a sterol transporter to mediate intestinal cholesterol absorption and counter-balances hepatobiliar

56 es by measuring plasma sterols as indexes of cholesterol absorption and endogenous synthesis.

57 Fractional cholesterol absorption and fecal neutral sterol excretio

58 Plasma markers of cholesterol absorption and hepatic cholesterol metabolis

59 s cholelithogenesis by promoting gallbladder cholesterol absorption and impairing gallbladder motilit

60 ficant suppression of the percentage dietary cholesterol absorption and increased gallbladder biliary

61 ty has been observed for rates of intestinal cholesterol absorption and LDL-C reductions at both base

62 ith large quantities of phytosterols reduces cholesterol absorption and LDL-cholesterol concentration

63 ore throw light on regulation of net dietary cholesterol absorption and lead to an advancement in the

64 respond have been identified as having high cholesterol absorption and low cholesterol biosynthesis.

65 (phytosterols) and the drug ezetimibe reduce cholesterol absorption and low-density lipoprotein chole

66 Plant sterol esters reduce cholesterol absorption and lower circulating blood chole

67 Ezetimibe inhibits intestinal cholesterol absorption and lowers low-density lipoprotei

68 of commercial corn oil substantially reduced cholesterol absorption and may account for part of the c

69 esis and plays a critical role in intestinal cholesterol absorption and pathogenesis of cholesterol g

70 any putative sterol transporters influencing cholesterol absorption and physical-chemical factors aff

71 tion in NPC1L1 contributes to variability in cholesterol absorption and plasma levels of low-density

72 cholesterol balance, including inhibition of cholesterol absorption and repressed bile acid synthesis

73 Studies of intestinal cholesterol absorption and reverse cholesterol transport

74 Gallbladder cholesterol absorption and size were significantly great

75 s a molecular pathway that regulates dietary cholesterol absorption and sterol excretion by the body.

76 intralumenal bile acid composition may alter cholesterol absorption and synthesis and low-density lip

77 Cholesterol absorption and synthesis were assessed by us

78 testinal NPC1L1 transporter is essential for cholesterol absorption and the maintenance of cholestero

79 of other studies suggest that it facilitates cholesterol absorption and the transfer of cholesterol i

80 Through integrated regulation of cholesterol absorption and TICE, the small intestine is

81 assess the contribution of these pathways to cholesterol absorption and to determine whether there ar

82 The strong association between intestinal cholesterol absorption and total plasma cholesterol leve

83 stinal transit times (resulting in increased cholesterol absorption), and increased biliary cholester

84 oncentrations, a 25% reduction in fractional cholesterol absorption, and a 4-fold elevation in fecal

85 f genes that regulate macrophage chemotaxis, cholesterol absorption, and fatty acid binding.

86 cholesterol secretion, decreased fractional cholesterol absorption, and increased fecal neutral ster

87 tanol and plant sterols provide a measure of cholesterol absorption, and lathosterol provides a measu

88 ed with abnormal immune function, intestinal cholesterol absorption, and lipid metabolism.

89 Those with low cholesterol absorption appear to benefit from treatment

90 e was primarily due to diminished intestinal cholesterol absorption as the result of changes in the c

91 ansporters ABCG5/8 and NPC1L1 and intestinal cholesterol absorption as well as de novo synthesis in g

92 Intestinal cholesterol absorption, as reflected by cholestanol-to-c

93 = 60 mg/kg) as measured in an acute hamster cholesterol absorption assay.

94 rol excretion and the decrease in fractional cholesterol absorption associated with LXR agonist treat

95 Sitostanol reduced cholesterol absorption at doses lower than reported prev

96 ces atherosclerosis by increasing intestinal cholesterol absorption, augmenting uptake of modified li

97 sterol ratio (CR) was used as an estimate of cholesterol absorption because it is independent of plan

98 ), small-intestinal transit time, intestinal cholesterol absorption, biliary cholesterol secretion, a

99 a new class of drugs that inhibit intestinal cholesterol absorption, blocks SR-BI- and CD36-facilitat

100 Compared to controls, cholesterol absorption but not synthesis in gallstone ca

101 ioleoyl ether phosphatidylcholine suppressed cholesterol absorption by 10% to 18% in mice without reg

102 ast, sitostanol in lecithin micelles reduced cholesterol absorption by 36.7 +/- 4.2% (P = 0.003) at a

103 HDCA supplementation decreased intestinal cholesterol absorption by 76% (P<0.0001) as compared wit

104 These data imply that CCK enhances cholesterol absorption by activation of a pathway involv

105 s indicate that phospholipase A2 may mediate cholesterol absorption by altering the physical-chemical

106 d hypercholesterolemia; increased intestinal cholesterol absorption by hydrophobic bile acids might c

107 Activation of FXR inhibits intestinal cholesterol absorption by modulation of bile acid pool s

108 Sitostanol powder (1 g) reduced cholesterol absorption by only 11.3 +/- 7.4% (P = 0.2),

109 s respond to the pharmacological blockade of cholesterol absorption by ramping up de novo sterol synt

110 derstanding about the mechanisms involved in cholesterol absorption by the intestinal cells.

111 sterol O-acyl transferase 2 (ACAT2) promotes cholesterol absorption by the intestine and the secretio

112 Physiological studies showed that enhanced cholesterol absorption by the intestine contributes to h

113 ncreatic secretion is required for efficient cholesterol absorption by the intestine, but the factors

114 However, reduction of cholesterol absorption can be measured at a dose of only

115 be, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovas

116 in an amount sufficient to block intestinal cholesterol absorption caused small intestinal transit t

117 s represent surrogate markers for intestinal cholesterol absorption, cholesterol precursors reflect c

118 e had a nearly 2-fold increase in intestinal cholesterol absorption compared with controls.

119 etary cholesterol consumption and intestinal cholesterol absorption contribute to plasma cholesterol

120 ts showed that high efficiency of intestinal cholesterol absorption contributes to gallstone formatio

121 Although NPC1L1 is required for intestinal cholesterol absorption, data demonstrating mechanisms by

122 Cholesterol absorption decreased as a result of PS consu

123 Intestinal cholesterol absorption decreases from 54 to 4% in knocko

124 Cholesterol absorption efficiency decreased (P = 0.010)

125 Under basal chow-fed dietary conditions, cholesterol absorption efficiency from a single bolus me

126 Cholesterol absorption efficiency was determined by feca

127 expression of an array of genes involved in cholesterol absorption, efflux, transport, and excretion

128 However, the LXR agonist T0901317 decreased cholesterol absorption equally in both wild type and WHA

129 ed steatorrhea, growth arrest, and decreased cholesterol absorption, features that collectively recap

130 Primary outcomes were intestinal cholesterol absorption, fecal cholesterol excretion, and

131 ever, it did not alter fractional intestinal cholesterol absorption, fecal neutral sterol excretion,

132 sterol (PPS) levels, a surrogate measure of cholesterol absorption from the intestine, where previou

133 Gallbladder motility and cholesterol absorption, gallstones and expression of the

134 Ezetimibe, a drug that inhibits cholesterol absorption, had no effect in NPC1L1 knockout

135 SCH 48461), a novel inhibitor of intestinal cholesterol absorption, has recently been described by B

136 physical-chemical factors affecting dietary cholesterol absorption have been extensively investigate

137 s, used as dietary complement for decreasing cholesterol absorption, have been synthesized at 28 degr

138 e and liver, which in turn limits intestinal cholesterol absorption, hepatic cholesterol gallstone fo

139 physiologic processes, including intestinal cholesterol absorption, hepatic lipoprotein production,

140 ing cholesterol is the balance among dietary cholesterol absorption, hepatic synthesis and secretion,

141 The PLA2 inhibitor FPL 67047XX retarded cholesterol absorption in a lymph fistula rat model.

142 rol precursor) was used to estimate relative cholesterol absorption in a population-based study.

143 sed plasma cholesterol levels and intestinal cholesterol absorption in both wild-type and LDLR(-/-) m

144 ezetimibe is equally effective in decreasing cholesterol absorption in Cav1 null mice and wild-type c

145 d in Cyp7a1-tg mice but intestine fractional cholesterol absorption in Cyp7a1-tg mice remained the sa

146 The role of cholic acid (CA) in cholesterol absorption in humans remains unclear and, th

147 l tissues, bile acid synthesis in liver, and cholesterol absorption in intestine.

148 nges occurred despite a relative decrease in cholesterol absorption in LD-fed Apobec-1(-/-) mice.

149 zing phospholipid digestion and facilitating cholesterol absorption in PLA2 knockout mice.

150 Over this range, fractional cholesterol absorption in the ACAT2(+/+) mice fell from

151 Human NPC1L1 protein mediates cholesterol absorption in the intestine and liver and is

152 By contrast, ACAT2 -/- mice have limited cholesterol absorption in the intestine, and decreased c

153 Modulation of cholesterol absorption in the intestine, the primary sit

154 Ezetimibe potently and selectively inhibits cholesterol absorption in the intestine, thereby reducin

155 -BI may be involved but is not essential for cholesterol absorption in the small intestine.

156 The question of whether SR-BI contributes to cholesterol absorption in vivo is still unresolved.

157 tedly, empagliflozin also reduced intestinal cholesterol absorption in vivo, which led to a significa

158 ss this issue, we measured beta-carotene and cholesterol absorption in wild-type and SR-BI knockout m

159 absence of changes in fractional intestinal cholesterol absorption, increased secretion of sterols i

160 in the setting of relatively low intestinal cholesterol absorption, indicating enhanced whole-body s

161 ter and the molecular target of ezetimibe, a cholesterol absorption inhibitor demonstrated to reduce

162 ike protein (NPC1L1) and is sensitive to the cholesterol absorption inhibitor ezetimibe (EZE).

163 ne formation, we explored whether the potent cholesterol absorption inhibitor ezetimibe could prevent

164 The cholesterol absorption inhibitor ezetimibe may offer a v

165 in enterocytes that can be disrupted by the cholesterol absorption inhibitor ezetimibe, suggesting a

166 absorption, a process that is sensitive to a cholesterol absorption inhibitor ezetimibe.

167 the last LDL-cholesterol-lowering drug, the cholesterol absorption inhibitor ezetimibe.

168 to those of wild type mice treated with the cholesterol absorption inhibitor ezetimibe.

169 the FXR agonist PX20606, with or without the cholesterol absorption inhibitor ezetimibe.

170 PC1L1 appears to be a target of ezetimibe, a cholesterol absorption inhibitor that effectively lowers

171 the molecular target of ezetimibe, a potent cholesterol absorption inhibitor that is widely used in

172 -dependently inhibited by ezetimibe, a novel cholesterol absorption inhibitor that specifically binds

173 ogether with the discovery of a new class of cholesterol absorption inhibitor, has yielded new insigh

174 The addition of ezetimibe, an intestinal cholesterol absorption inhibitor, to statin therapy has

175 Ezetimibe (1), a strong beta-lactamic cholesterol absorption inhibitor, was synthesized from (

176 Ezetimibe is a selective cholesterol absorption inhibitor, with a site of action

177 ive preparation of Ezetimibe, the commercial cholesterol absorption inhibitor.

178 the intestine, a process that is blocked by cholesterol absorption inhibitors (CAIs), including ezet

179 own about intestinal sterol transporters and cholesterol absorption inhibitors (CAIs).

180 A series of azetidinone cholesterol absorption inhibitors related to SCH 48461 (

181 explored the use of steroidal glycosides as cholesterol absorption inhibitors which act through an u

182 ms to further probe the SAR of 2-azetidinone cholesterol absorption inhibitors.

183 1' position provided compounds with improved cholesterol absorption inhibitory activity.

184 Cholesterol absorption is a key regulatory point in huma

185 These findings indicate that cholesterol absorption is a multistep process that is re

186 Cholesterol absorption is a selective process in that pl

187 The inhibition of cholesterol absorption is an important therapeutic strat

188 High cholesterol absorption is associated with risk alleles i

189 Increasingly, new studies suggest that cholesterol absorption is genetically controlled and sup

190 icating that the effect of LXR activation on cholesterol absorption is independent of ABCA1.

191 The mechanism of cholesterol absorption is not completely known but invol

192 r mechanism by which these compounds inhibit cholesterol absorption is unknown.

193 tral sterol secretion and reduces intestinal cholesterol absorption, leading to a selective increase

194 In two extended families, mean cholesterol absorption levels, as measured using stable

195 and whole-body sterol homeostasis, including cholesterol absorption, lipoprotein synthesis and remode

196 erol/cholesterol and sitosterol/cholesterol (cholesterol absorption markers) had decreasing order in

197 enterocyte level and that the efficiency of cholesterol absorption may be determined by the net effe

198 ze that ezetimibe, which inhibits intestinal cholesterol absorption, may not exert similar cholestero

199 e fecal cholesterol excretion and intestinal cholesterol absorption measured with stable-isotope trac

200 To determine fractional cholesterol absorption, mice were given intravenous inje

201 mechanisms by which inhibition of intestinal cholesterol absorption might contribute to the clinicall

202 had significantly lower levels of intestinal cholesterol absorption, more fecal sterol excretion, and

203 Combination therapy using cholesterol absorption (NPC1L1) inhibitor (ezetimibe) an

204 udies suggest that, when soy protein is fed, cholesterol absorption or bile acid reabsorption, or bot

205 ts demonstrate that CAV1 is not required for cholesterol absorption or ezetimibe sensitivity in the m

206 ffect biliary cholesterol levels, fractional cholesterol absorption, or neutral fecal sterol excretio

207 at 24 weeks of age showed a 27% decrease in cholesterol absorption (P < .001) and reduced levels of

208 (ABCG5/ABCG8), which affects the intestinal cholesterol absorption pathway targeted by BAS and then

209 ys a crucial role in the ezetimibe-sensitive cholesterol absorption pathway.

210 oprotein B (apoB)-dependent and -independent cholesterol absorption pathways and the role of microsom

211 tte transporter A1 gene regulates intestinal cholesterol absorption, perhaps by mediating cholesterol

212 Measurements of serum surrogate markers of cholesterol absorption (plant sterols: sitosterol, campe

213 ed hepatic cholesterol uptake and intestinal cholesterol absorption play an essential role in LXR-pro

214 rsely correlated with the percentage dietary cholesterol absorption (r = -0.63, P < 0.0001).

215 sought to investigate whether the individual cholesterol absorption rate affects atorvastatin's effec

216 Harm caused by elevated cholesterol absorption rather than by plant sterols may

217 The most pronounced effect on cholesterol absorption ratio was observed for serum camp

218 er treatment with ezetimibe, an inhibitor of cholesterol absorption, reduces plant sterol levels in p

219 esterol transporter essential for intestinal cholesterol absorption, reduces the output of dry stool

220 sought to determine whether high intestinal cholesterol absorption represents a cardiovascular risk

221 Intestinal cholesterol absorption represents a major route for the

222 Cholesterol absorption results were similar between the

223 We determined whether differences in cholesterol absorption, synthesis, or both could be resp

224 atic Abcg5/8 expression and limiting dietary cholesterol absorption, T39 deficiency inhibits hepatic

225 antly more common among individuals with low cholesterol absorption than in those with high cholester

226 Ezetimibe is a potent inhibitor of cholesterol absorption that has been approved for the tr

227 conclusion, although ACAT2 deficiency limits cholesterol absorption, the extent to which it impacts h

228 icate that upregulation of the gene inhibits cholesterol absorption, the results of other studies sug

229 LXR) agonists have been inferred to decrease cholesterol absorption through activation of ABCA1 expre

230 suggested phospholipid inhibition of dietary cholesterol absorption through the gastrointestinal trac

231 ol esterase (bile salt-stimulated lipase) in cholesterol absorption through the intestine has been co

232 or either one of them diminished CCK-induced cholesterol absorption to the same extent.

233 Ezetimibe interacts with the intestinal cholesterol absorption transporter NPC1l1 to block chole

234 ) on plasma cholesterol level and intestinal cholesterol absorption using the in vivo models of C57BL

235 Cholesterol absorption was 38.0 +/- 10.2% higher after c

236 Cholesterol absorption was 41% lower in PTL(-/-) mice co

237 Cholesterol absorption was about 24% lower in individual

238 The regulation of dietary cholesterol absorption was examined in C57BL/6 and trans

239 Cholesterol absorption was highest in the LIS participan

240 The ability of sitostanol to reduce cholesterol absorption was measured directly by includin

241 oil at a concentration of 150 mg/test meal, cholesterol absorption was reduced by 12.1 +/- 3.7% (P =

242 Acute cholesterol absorption was reduced by 28% in the absence

243 on was increased only 3-fold, and intestinal cholesterol absorption was reduced only 20%, indicating

244 We found that cholesterol absorption was significantly decreased as a

245 Pharmacological blockade of cholesterol absorption was unable to further induce the

246 CA1, previously implicated in the control of cholesterol absorption, was also dramatically up-regulat

247 Cholesterol synthesis and change in cholesterol absorption were measured with stable isotopi

248 ratio, which is an established biomarker of cholesterol absorption, were used to identify high and l

249 fter emulsification with lecithin and reduce cholesterol absorption when added to nonfat foods.

250 sterifies absorbed cholesterol and increases cholesterol absorption when dietary intake is high.

251 ng phytosterols from corn oil would increase cholesterol absorption when measured in single-meal test

252 al cells with [Thr(28),Nle(31)]CCK increased cholesterol absorption, whereas selective inhibition of

253 , a novel, potent and selective inhibitor of cholesterol absorption which is effective in milligram d

254 ingly, empagliflozin also reduces intestinal cholesterol absorption, which in turn promotes LDL- and

255 Inhibition of intestinal cholesterol absorption with ezetimibe promotes antiather